BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:STI-6129 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of STI-6129\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05565807-3172@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:STI-6129: Phase 1/2 readout est. (NCT05565807)
DESCRIPTION:STI-6129\, phase 1/2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refract
 ory Multiple Myeloma\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sti-6129#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05565807
URL:https://assetmemo.bio/drug/sti-6129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
